Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801556 | 0.95 | LIPG (0.47) | TLR8LIPGNR1H2NR1H3KCNH2 | |
| SCHEMBL3630731 | 0.89 | GRM5 (0.37) | TLR8KCNH2ELANE | |
| SCHEMBL13505762 | 0.86 | TLR8 (0.41) | TLR8LIPGNR1H2NR1H3KCNH2 | |
| SCHEMBL12668160 | 0.83 | LIPG (0.42) | TLR8LIPGNR1H2NR1H3CYP3A4 | |
| SCHEMBL4725082 | 0.82 | CYP1A2 (0.49) | LIPGNR1H2NR1H3CYP2D6CYP2C9 | |
| SCHEMBL2701240 | 0.82 | LIPG (0.50) | TLR8LIPGNR1H2NR1H3CYP3A4 | |
| SCHEMBL13505989 | 0.81 | LIPG (0.41) | TLR8LIPGNR1H2NR1H3CYP3A4 | |
| SCHEMBL26184932 | 0.80 | TLR8 (0.43) | TLR8CYP3A4ELANE | |
| SCHEMBL3629022 | 0.80 | TLR8 (0.45) | TLR8KCNH2CYP2D6 | |
| SCHEMBL7234942 | 0.77 | ALOX5 (0.51) | LIPGNR1H2NR1H3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2208722-A1 | PROCESS FOR PRODUCTION OF DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALYST, PROCESS FOR PRODUCTION OF -AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE SALT | National University Corporation Nagoya University (JP) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | MGAT2, MPST, MGAT1 | TLR8 4464/4885LIPG 668/4885NR1H2 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.